Enveric Biosciences (ENVB) Cash from Financing Activities (2011 - 2026)

Enveric Biosciences has reported Cash from Financing Activities for 16 years, with the latest figure at $2.5 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 43.73% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (up 58.0% YoY) and the FY2025 annual result came in at $10.6 million, up 37.86% from the prior year.
• Cash from Financing Activities slipped to $2.5 million in Q1 2026 per ENVB's latest filing, from $2.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $9.4 million in Q1 2022 and troughed at -$186084.0 in Q4 2023.
• A 5-year average of $2.6 million and a median of $958038.0 in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities jumped 86935833.33% in 2022, then tumbled 18608300.0% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$1.0 in 2022, then sank by 18608300.0% to -$186084.0 in 2023, then surged by 349.05% to $463448.0 in 2024, then soared by 480.25% to $2.7 million in 2025, then retreated by 6.91% to $2.5 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.5 million, $2.7 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.